Shopping Cart
- Remove All
Your shopping cart is currently empty
EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.

| Description | EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research. |
| Targets&IC50 | EGFR:48.6 nM, PD-L1:1.77 μM |
| In vitro | EP26 (0-4 µM; 48 h) reduces p-EGFR protein expression in a dose-dependent manner. At concentrations of 0.5, 1, and 2 µM, EP26 (48 h) induces cell cycle arrest at the G0/G1 phase. Additionally, EP26 binds to human PD-L1 and mouse PD-L1 in a dose-dependent fashion, with K D values of 0.58 and 0.52 µM, respectively. |
| In vivo | EP26 (50, 100 mg/kg; p.o.; once daily for 21 days) demonstrates antitumor activity in mice. |
| Formula | C42H42ClFN4O5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.